NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies
ID1442

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company • Celgene, a BMS company (idecabtagene vicleucel) Patient/carer group • African Caribbean Leukaemia Trust • Black Health Agency • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Leukaemia UK • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Myeloma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Professional groups • Association of Cancer Physicians • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • Advanz Pharma (dexamethasone) • Aspen (dexamethasone, melphalan) • Aspire (bortezomib, dexamethasone) • Baxter Healthcare (cyclophosphamide) • Celgene, a BMS company (pomalidomide) • Consilient Health (dexamethasone) • Dr Reddy's Laboratories (bortezomib) • Ethypharm (dexamethasone) • Glenmark Pharmaceuticals (dexamethasone) • Janssen-Cilag (bortezomib)

Consultees	Commentators (no right to submit or appeal)
• British Psychosocial Oncology Society • British Society for Haematology • British Transplantation Society • Cancer Research UK • Efficacy and Safety of Prescribing in Transplantation (ESPRIT) Group • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Myeloma Forum • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS Blackpool CCG • NHS England • NHS Harrogate and Rural District CCG • Welsh Government	• Novartis (panobinostat) • Panpharma UK (dexamethasone) • Pfizer (dexamethasone) • Rosemont Pharmaceuticals (dexamethasone) • Sandoz (cyclophosphamide) • Thame Laboratories (dexamethasone) • Thornton & Ross (bortezomib) • Wockhardt UK (dexamethasone) <u>Relevant research groups</u> • Cochrane Haematological Malignancies Group • Genomics England • Institute of Cancer Research • Leuka • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies;
Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

[1]Non-company consultees are invited to submit statements relevant to the group they are representing.

